Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.

Bays, Harold E; Rosenson, Robert S; Baccara-Dinet, Marie T; Louie, Michael J; Thompson, Desmond; Kees Hovingh, G

Bays, Harold E; Rosenson, Robert S; Baccara-Dinet, Marie T; Louie, Michael J; Thompson, Desmond; Kees Hovingh, G.

Afiliación

Bays HE; Departments of Epidemiology & Medicine, Louisville Metabolic and Atherosclerosis Research Center (L-MARC), 3288 Illinois Avenue, Louisville, KY, 40213, USA. hbaysmd@outlook.com.
Rosenson RS; Cardiometabolics Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Baccara-Dinet MT; Clinical Development, R&D, Sanofi, Montpellier, France.
Louie MJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Thompson D; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Kees Hovingh G; Department of Vascular Medicine - Internal Medicine Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Cardiovasc Drugs Ther ; 32(2): 181, 2018 04.

Article en En | MEDLINE | ID: mdl-29713852

RESUMEN

The original version of this article unfortunately contained a mistake in the Discussion section.

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cardiovasc Drugs Ther Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google